Octamoxin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Octamoxin
Accession Number
DB09249
Type
Small Molecule
Groups
Withdrawn
Description

Octamoxin (trade names Ximaol, Nimaol), also known as 2-octylhydrazine, is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant in the 1960s but is now no longer marketed.

Structure
Thumb
Synonyms
  • 2-octylhydrazine
International/Other Brands
Nimaol / Ximaol
Categories
UNII
0HXY3M6S54
CAS number
4684-87-1
Weight
Average: 144.262
Monoisotopic: 144.162648652
Chemical Formula
C8H20N2
InChI Key
FODQIVGFADUBKE-UHFFFAOYSA-N
InChI
InChI=1S/C8H20N2/c1-3-4-5-6-7-8(2)10-9/h8,10H,3-7,9H2,1-2H3
IUPAC Name
(octan-2-yl)hydrazine
SMILES
CCCCCCC(C)NN

Pharmacology

Indication

For the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Octamoxin.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Octamoxin.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Octamoxin.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Octamoxin.Experimental, Illicit
4-MethoxyamphetamineOctamoxin may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Octamoxin.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineOctamoxin may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Abediterol.Investigational
AcarboseOctamoxin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololOctamoxin may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Octamoxin.Experimental
AlbiglutideOctamoxin may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Octamoxin.Approved, Illicit
AliskirenOctamoxin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Octamoxin.Approved, Investigational
AlogliptinOctamoxin may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Octamoxin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Octamoxin.Illicit
AlprenololOctamoxin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Octamoxin.Approved
AmbrisentanOctamoxin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineOctamoxin may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineOctamoxin may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideOctamoxin may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineOctamoxin may increase the hypotensive activities of Amlodipine.Approved
AmoxapineOctamoxin may increase the serotonergic activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Octamoxin.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Octamoxin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Arformoterol.Approved, Investigational
AtenololOctamoxin may increase the hypotensive activities of Atenolol.Approved
AtomoxetineOctamoxin may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineOctamoxin may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bambuterol.Approved, Investigational
BenazeprilOctamoxin may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideOctamoxin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Octamoxin.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Octamoxin.Approved, Illicit
BepridilOctamoxin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Octamoxin.Approved, Investigational
BetaxololOctamoxin may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineOctamoxin may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bezafibrate.Approved, Investigational
BietaserpineOctamoxin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostOctamoxin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololOctamoxin may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bitolterol.Withdrawn
BosentanOctamoxin may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Octamoxin may increase the hypotensive activities of BQ-123.Investigational
BretyliumOctamoxin may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Octamoxin.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Brimonidine.Approved
BrofaromineOctamoxin may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Octamoxin.Approved, Investigational
BupranololOctamoxin may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Octamoxin.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Octamoxin is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Octamoxin is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Octamoxin.Approved, Illicit, Vet Approved
ButriptylineOctamoxin may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Octamoxin.Approved
CadralazineOctamoxin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineOctamoxin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinOctamoxin may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanOctamoxin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilOctamoxin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilOctamoxin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilOctamoxin may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Octamoxin.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Octamoxin.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Octamoxin.Approved, Investigational
CaroxazoneOctamoxin may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololOctamoxin may increase the hypotensive activities of Carteolol.Approved
CarvedilolOctamoxin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololOctamoxin may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideOctamoxin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Octamoxin.Illicit, Withdrawn
ChlorpropamideOctamoxin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneOctamoxin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineOctamoxin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilOctamoxin may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Octamoxin.Approved, Investigational
CirazolineOctamoxin may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Octamoxin.Approved
ClemastineOctamoxin may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineOctamoxin may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineOctamoxin may increase the hypertensive activities of Clonidine.Approved
CloranololOctamoxin may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Octamoxin.Approved, Illicit
CryptenamineOctamoxin may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Octamoxin.Approved
CyclopenthiazideOctamoxin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideOctamoxin may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineOctamoxin may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinOctamoxin may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Octamoxin.Investigational
DebrisoquinOctamoxin may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilOctamoxin may increase the hypotensive activities of Delapril.Experimental
DeserpidineOctamoxin may increase the hypotensive activities of Deserpidine.Approved
DesipramineOctamoxin may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Octamoxin.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateOctamoxin may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineThe risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Octamoxin.Approved, Illicit
DextromethorphanOctamoxin may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Octamoxin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Octamoxin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Octamoxin.Approved, Investigational
DiazoxideOctamoxin may increase the hypotensive activities of Diazoxide.Approved
DibenzepinOctamoxin may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineOctamoxin may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionOctamoxin may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineOctamoxin may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Octamoxin.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Octamoxin.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Octamoxin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Octamoxin.Experimental, Illicit
DiltiazemOctamoxin may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineOctamoxin may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Octamoxin.Approved, Illicit
DipivefrinOctamoxin may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideOctamoxin may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Octamoxin is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideOctamoxin may increase the hypotensive activities of Dorzolamide.Approved
DosulepinOctamoxin may increase the serotonergic activities of Dosulepin.Approved
DoxapramOctamoxin may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinOctamoxin may increase the hypotensive activities of Doxazosin.Approved
DoxepinOctamoxin may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Doxofylline.Approved, Investigational
DoxylamineOctamoxin may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Octamoxin.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Octamoxin.Experimental, Illicit
DroxidopaOctamoxin may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideOctamoxin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Octamoxin.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Octamoxin.Experimental, Illicit
EfonidipineOctamoxin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Octamoxin.Approved, Investigational
EmpagliflozinOctamoxin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilOctamoxin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatOctamoxin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineOctamoxin may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Octamoxin.Approved, Investigational
EpanololOctamoxin may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Octamoxin is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineOctamoxin may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolOctamoxin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanOctamoxin may increase the hypotensive activities of Eprosartan.Approved
ErgonovineOctamoxin may increase the hypertensive activities of Ergonovine.Approved
ErgotamineOctamoxin may increase the hypertensive activities of Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Octamoxin.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Octamoxin.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Octamoxin.Approved, Illicit
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Octamoxin.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Octamoxin.Illicit, Vet Approved
ExenatideOctamoxin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineOctamoxin may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineOctamoxin may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamOctamoxin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Octamoxin.Approved, Illicit, Investigational, Vet Approved
Ferulic acidOctamoxin may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Octamoxin.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Octamoxin.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Octamoxin.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Formoterol.Approved, Investigational
FosinoprilOctamoxin may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Octamoxin.Approved, Investigational
FurazolidoneOctamoxin may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Octamoxin.Experimental
GliclazideOctamoxin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOctamoxin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOctamoxin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideOctamoxin may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzOctamoxin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelOctamoxin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineOctamoxin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineOctamoxin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineOctamoxin may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorOctamoxin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzOctamoxin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanOctamoxin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineOctamoxin may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Octamoxin.Approved, Illicit, Investigational
HexamethoniumOctamoxin may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the hypertensive activities of Octamoxin.Experimental
HydralazineOctamoxin may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideOctamoxin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Octamoxin.Approved, Illicit
HydroflumethiazideOctamoxin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Octamoxin.Approved, Illicit
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Octamoxin.Approved
ImidaprilOctamoxin may increase the hypotensive activities of Imidapril.Investigational
ImipramineOctamoxin may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Octamoxin.Investigational, Withdrawn
IndapamideOctamoxin may increase the hypotensive activities of Indapamide.Approved
IndenololOctamoxin may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminOctamoxin may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartOctamoxin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOctamoxin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOctamoxin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOctamoxin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOctamoxin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOctamoxin may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Octamoxin.Approved
IprindoleOctamoxin may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Octamoxin.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Octamoxin.Withdrawn
IrbesartanOctamoxin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Octamoxin.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Isoprenaline.Approved, Investigational
IsradipineOctamoxin may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinOctamoxin may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Octamoxin.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Octamoxin.Approved, Nutraceutical, Withdrawn
LabetalolOctamoxin may increase the hypotensive activities of Labetalol.Approved
LacidipineOctamoxin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostOctamoxin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineOctamoxin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Octamoxin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Octamoxin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Octamoxin.Approved, Investigational
LevonordefrinOctamoxin may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Octamoxin.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Octamoxin is combined with Linezolid.Approved, Investigational
LinsidomineOctamoxin may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideOctamoxin may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineThe risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Octamoxin.Approved, Investigational
LisinoprilOctamoxin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Octamoxin.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Octamoxin is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Octamoxin.Illicit
LofepramineOctamoxin may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Octamoxin.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Octamoxin.Approved
LosartanOctamoxin may increase the hypotensive activities of Losartan.Approved
MacitentanOctamoxin may increase the hypotensive activities of Macitentan.Approved
ManidipineOctamoxin may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the hypertensive activities of Octamoxin.Withdrawn
MecamylamineOctamoxin may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminOctamoxin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenOctamoxin may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Mephedrone is combined with Octamoxin.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Octamoxin.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Octamoxin.Experimental
MequitazineOctamoxin may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolOctamoxin may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminOctamoxin may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Octamoxin.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Octamoxin.Approved, Illicit
MethoserpidineOctamoxin may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineOctamoxin may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Octamoxin.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Octamoxin is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Octamoxin.Experimental
Methylene blueOctamoxin may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateOctamoxin may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Octamoxin.Approved
MetipranololOctamoxin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneOctamoxin may increase the hypotensive activities of Metolazone.Approved
MetoprololOctamoxin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineOctamoxin may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Mianserin.Approved, Investigational
MibefradilOctamoxin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineOctamoxin may increase the hypertensive activities of Midodrine.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Octamoxin.Experimental, Illicit, Investigational
MifepristoneOctamoxin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolOctamoxin may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Octamoxin.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Octamoxin.Approved
MinoxidilOctamoxin may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Mirtazapine.Approved
MMDAThe risk or severity of adverse effects can be increased when MMDA is combined with Octamoxin.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Octamoxin is combined with Moclobemide.Approved, Investigational
MoexiprilOctamoxin may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Octamoxin.Approved, Investigational
MoxonidineOctamoxin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineOctamoxin may increase the hypotensive activities of Muzolimine.Experimental
NadololOctamoxin may increase the hypotensive activities of Nadolol.Approved
NaftopidilOctamoxin may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Octamoxin.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Octamoxin.Investigational
NaphazolineOctamoxin may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe serum concentration of Naratriptan can be increased when it is combined with Octamoxin.Approved, Investigational
NateglinideOctamoxin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololOctamoxin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Octamoxin.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Octamoxin.Withdrawn
NicardipineOctamoxin may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilOctamoxin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineOctamoxin may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineOctamoxin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineOctamoxin may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineOctamoxin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineOctamoxin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideOctamoxin may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineOctamoxin may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Octamoxin.Approved, Illicit
NortriptylineOctamoxin may increase the serotonergic activities of Nortriptyline.Approved
OlanzapineOctamoxin may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanOctamoxin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Olodaterol.Approved
OmapatrilatOctamoxin may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolOctamoxin may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Octamoxin.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Orciprenaline.Approved
OxprenololOctamoxin may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Octamoxin is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineOctamoxin may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Octamoxin.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Octamoxin.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Octamoxin.Approved, Investigational
PenbutololOctamoxin may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineOctamoxin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Octamoxin.Approved, Vet Approved
PentoliniumOctamoxin may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Octamoxin.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilOctamoxin may increase the hypotensive activities of Perindopril.Approved
PethidineOctamoxin may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Octamoxin is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Octamoxin.Experimental
PhendimetrazineOctamoxin may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Octamoxin.Approved
PheniprazineOctamoxin may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Octamoxin.Experimental
PhenoxybenzamineOctamoxin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineOctamoxin may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Octamoxin.Approved, Illicit
PhentolamineOctamoxin may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineOctamoxin may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Octamoxin.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Octamoxin.Investigational
PinacidilOctamoxin may increase the hypotensive activities of Pinacidil.Approved
PindololOctamoxin may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneOctamoxin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Octamoxin.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Octamoxin.Approved
PivhydrazineOctamoxin may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenOctamoxin may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorOctamoxin may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideOctamoxin may increase the hypotensive activities of Polythiazide.Approved
PramlintideOctamoxin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinOctamoxin may increase the hypotensive activities of Prazosin.Approved
ProcaineOctamoxin may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineOctamoxin may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Procaterol.Approved, Investigational
PropranololOctamoxin may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Protokylol.Approved, Vet Approved
ProtriptylineOctamoxin may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Octamoxin.Approved
QuinaprilOctamoxin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineOctamoxin may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineOctamoxin may increase the hypertensive activities of Racepinephrine.Approved
RamiprilOctamoxin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Octamoxin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Octamoxin.Approved
RemikirenOctamoxin may increase the hypotensive activities of Remikiren.Approved
RepaglinideOctamoxin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineOctamoxin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Reserpine.Approved, Investigational
RilmenidineOctamoxin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatOctamoxin may increase the hypotensive activities of Riociguat.Approved
RitobegronThe risk or severity of adverse effects can be increased when Ritobegron is combined with Octamoxin.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Ritodrine.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Octamoxin.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Octamoxin.Approved, Investigational
RosiglitazoneOctamoxin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Octamoxin.Approved
SafrazineOctamoxin may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salmeterol.Approved
SaprisartanOctamoxin may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinOctamoxin may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Octamoxin.Approved, Investigational, Vet Approved
SelexipagOctamoxin may increase the hypotensive activities of Selexipag.Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Octamoxin.Approved
SitagliptinOctamoxin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanOctamoxin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilOctamoxin may increase the hypotensive activities of Spirapril.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Octamoxin.Approved, Investigational
SulfadiazineOctamoxin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleOctamoxin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleOctamoxin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Octamoxin.Approved, Investigational
SunitinibOctamoxin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololOctamoxin may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Octamoxin.Approved
TelmisartanOctamoxin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilOctamoxin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Terbutaline.Approved
TerlipressinOctamoxin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Octamoxin is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Octamoxin.Investigational
TetrahydropalmatineOctamoxin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineOctamoxin may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineOctamoxin may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Octamoxin.Approved, Investigational
TiboloneOctamoxin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenOctamoxin may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Octamoxin.Experimental
TimololOctamoxin may increase the hypotensive activities of Timolol.Approved
TolazamideOctamoxin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineOctamoxin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideOctamoxin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Octamoxin.Approved, Withdrawn
TolonidineOctamoxin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Octamoxin.Approved
TorasemideOctamoxin may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Octamoxin.Approved, Investigational
TrandolaprilOctamoxin may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Octamoxin.Approved, Investigational
TravoprostOctamoxin may increase the hypotensive activities of Travoprost.Approved
TrazodoneOctamoxin may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilOctamoxin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideOctamoxin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinOctamoxin may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanOctamoxin may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineOctamoxin may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneOctamoxin may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilOctamoxin may increase the hypotensive activities of Urapidil.Investigational
ValsartanOctamoxin may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Octamoxin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Octamoxin is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Octamoxin.Approved
VincamineOctamoxin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineOctamoxin may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Octamoxin.Approved, Investigational
XipamideOctamoxin may increase the hypotensive activities of Xipamide.Experimental
XylometazolineOctamoxin may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Octamoxin.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Octamoxin.Approved
ZofenoprilOctamoxin may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Octamoxin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Gayral L, Stern H, Puyuelo R: [Indications and results of the treatment of mental depression by octamoxine (ximaol)]. Therapie. 1966 Sep-Oct;21(5):1183-90. [PubMed:5976767]
External Links
PubChem Compound
20811
PubChem Substance
310265152
ChemSpider
19587
ChEBI
134768
ChEMBL
CHEMBL2104528
Wikipedia
Octamoxin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.27 mg/mLALOGPS
logP2.54ALOGPS
logP2.26ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)5.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area38.05 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity56.99 m3·mol-1ChemAxon
Polarizability19.11 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkylhydrazines. These are organonitrogen compounds that containing a hydrazine group to which an alkyl group is attached.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Hydrazines and derivatives
Direct Parent
Alkylhydrazines
Alternative Parents
Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alkylhydrazine / Organopnictogen compound / Hydrocarbon derivative / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 22:02 / Updated on June 02, 2018 08:18